| Literature DB >> 34870173 |
Zübeyde Tuğçe Korucu1, İlknur Onurlu2, Alperen Korucu3, Zafer Günendi2.
Abstract
OBJECTIVES: This study aims to investigate the effect of a supervised dynamic exercise program on somatosensory temporal discrimination (STD) which indicates the central sensory processing ability. PATIENTS AND METHODS: Forty-eight patients (mean age: 43 years; range, 19 to 64 years) with fibromyalgia syndrome (FMS) were included in this prospective, randomized study between April 2018 and October 2018. Demographics and clinical measurements were recorded. The STD threshold was measured by a researcher blinded to the treatment groups. After baseline assessments, the patients were randomized into two groups: the supervised exercise group (SEG) and the home exercise group (HEG) as the control group. The SEG performed submaximal aerobic exercise and low-medium resistant isotonic exercises under the supervision of a physiotherapist, 1-h per day, three days in a week for four weeks. The HEG was given a home-based exercise program consisting of low-to-medium resistance isotonic exercises and aerobic exercises 1-h per day, three days in a week for four weeks. After exercise program, clinical assessments and STD threshold measurement were repeated.Entities:
Keywords: Exercise; fibromyalgia; somatosensory temporal discrimination
Year: 2021 PMID: 34870173 PMCID: PMC8612498 DOI: 10.46497/ArchRheumatol.2021.8412
Source DB: PubMed Journal: Arch Rheumatol ISSN: 2148-5046 Impact factor: 1.472
Figure 1Study flow chart.
Demographic data, baseline clinical and neurophysiological characteristics of the groups
| Supervised exercise group (n=24) | Home exercise group (n=24) | Mean difference | 95% Cl | ||||||
| Mean±SD | Median | IQR | Mean±SD | Median | IQR | ||||
| Age (year) | 42.2±11.3 | 43 | 37.5-51 | 43.1±12.9 | 43 | 31.5-54.7 | -0.8 | -7.9-6.2 | 0.805 |
| Body mass index (kg/m2) | 27.3±4.7 | 26.9 | 23-27 | 25.4±4.2 | 24.7 | 22.7-28.3 | 1.9 | -0.6-4.5 | 0.146 |
| Education time (year) | 11.8±3.7 | 12 | 8-16 | 11.9±3.6 | 12 | 8-16 | -0.08 | -2.2-2 | 0.914 |
| The time since diagnosis (month) | 21.2±37.9 | 9 | 6-12 | 24.5±32.5 | 7.5 | 2-33 | -3.2 | -23-17 | 0.475 |
| Visual Analog Scale | 7.7±1.6 | 8 | 7-9 | 7.5±1.3 | 7.7 | 7-8.8 | 0.2 | -0.7-1.1 | 0.658 |
| HAD-A score | 11.8±4.6 | 13 | 8-16 | 11.3±4.9 | 12 | 6.2-15.7 | 0.5 | -2.2-3.3 | 0.664 |
| HAD-D score | 8.8±3.7 | 9 | 5.2-11.7 | 8.8±4.3 | 9.5 | 6-12.7 | -0.04 | -2.3-3.3 | 0.972 |
| FIQ score | 61.2±18 | 68 | 45.1-76 | 60±20.7 | 57.5 | 44.7-78.4 | 1.1 | -10-12 | 0.967 |
| SSS score | 9±2.2 | 10 | 7-10.7 | 9.6±2.3 | 10 | 8.2-12 | -0.5 | -1.8-0.8 | 0.357 |
| STDT | 81.6±16.8 | 80.6 | 74-88.6 | 79.3±26.4 | 77.5 | 58.7-93.1 | 2.2 | -10-15 | 0.727 |
| SD: Standard derivation; IQR: Interquartile range; CI: Confidence interval; HAD-A/HAD-D: Hospital Anxiety and Depression Scale; FIQ: Fibromyalgia Impact Questionnaire; SSS: Symptom Severity Scale; STDT: Somatosensory temporal discrimination threshold. | |||||||||
Changes in clinical and neurophysiological measures between baseline and fourth week evaluations
| Mean±SD | Median | IQR | Mean±SD | Median | IQR | |
| Visual Analog Scale | ||||||
| Baseline | 7.7±1.6 | 8 | 7-9 | 7.5±1.3 | 7.7 | 7-8.8 |
| At Week 4 | 3.6±1.9 | 3 | 2-5 | 4.7±2.1 | 4 | 3-6.7 |
| <0.001 | <0.001 | |||||
| HADA score | ||||||
| Baseline | 11.8±4.6 | 13 | 8-16 | 11.3±4.9 | 12 | 6.2-15.7 |
| At Week 4 | 6.08±3.5 | 5 | 3-8 | 8.2±4.8 | 6.5 | 4.2-11.7 |
| <0.001 | <0.001 | |||||
| HADD score | ||||||
| Baseline | 8.8±3.7 | 9 | 5.2-11.7 | 8.8±4.3 | 9.5 | 6-12.7 |
| At Week 4 | 4.5±1.9 | 4 | 3.25-8 | 6.6±4 | 6 | 4-9.5 |
| p | <0.001 | <0.001 | ||||
| FIQ score | ||||||
| Baseline | 61.2±18 | 68 | 45.1-76 | 60±20.7 | 57.5 | 44.7-78.4 |
| At Week 4 | 30.5±16.7 | 29 | 17.6-41.7 | 43.2±18.5 | 40.4 | 27.7-55.5 |
| p | <0.001 | <0.001 | ||||
| SSS score | ||||||
| Baseline | 9±2.2 | 10 | 7-10.7 | 9.6±2.3 | 10 | 8.2-12 |
| At Week 4 | 4.9±2.05 | 4 | 4-6.7 | 6.8±2.4 | 7 | 4.2-8.7 |
| p | <0.001 | <0.001 | ||||
| STDT | ||||||
| Baseline | 81.6±16.8 | 80.6 | 74-88.6 | 79.3±26.4 | 77.5 | 58.7-93.1 |
| At Week 4 | 73.3±16 | 73.1 | 66.8-80.9 | 73.3±24.9 | 72.5 | 53.7-89 |
| <0.001 | <0.001 | |||||
| SD: Standard derivation; IQR: Interquartile range; HAD-A/HAD-D: Hospital Anxiety and Depression Scale; FIQ: Fibromyalgia Impact Questionnaire; SSS: Symptom Severity Scale; STDT: Somatosensory temporal discrimination threshold. | ||||||
Figure 2(a-c) Changes between the pain measurements at baseline and at Week 4. HAD-A. HAD-D scores in both groups. SEG: Supervised exercise group; HEG: Home exercise group; VAS: Visual Analog Scale; HAD-A: Hospital Anxiety and Depression Scale-Anxiety; HAD-D: Hospital Anxiety and Depression Scale-Depression.
Figure 3(a-c) Changes between baseline and 4th Week measurements in FIQ and SSS scores and STDT measures in both groups. SEG: Supervised exercise group; HEG: Home exercise group; FIQ: Fibromyalgia Impact Questionnaire; SSS: Symptom Severity Scale; STDT: Somatosensory temporal discrimination threshold.
Correlation analysis results
| Age | Education time | The time since diagnosis | VAS | HAD-A | HAD-D | FIQ | SSS | STDT | |
| Age | |||||||||
| r | 1.00 | -0.14 | -0.17 | -0.08 | -0.36 | -0.17 | -0.22 | -0.18 | 0.29 |
| 0.333 | 0.242 | 0.581 | 0.242 | 0.128 | 0.206 | ||||
| Education time | |||||||||
| r | -0.14 | 1.00 | -0.23 | -0.44 | -0.26 | -0.51 | -0.31 | -0.24 | 0.44 |
| 0.333 | 0.108 | 0.071 | 0.088 | 0.767 | |||||
| The time since diagnosis | |||||||||
| r | -0.02 | -0.23 | 1.00 | 0.11 | 0.14 | 0.25 | 0.21 | 0.31 | 0.15 |
| 0.847 | 0.108 | 0.44 | 0.343 | 0.08 | 0.142 | 0.31 | |||
| VAS | |||||||||
| r | -0.82 | -0.44 | 0.11 | 1.00 | 0.61 | 0.53 | 0.72 | 0.48 | -0.38 |
| 0.581 | 0.001 | 0.44 | 0.799 | ||||||
| HAD-A | |||||||||
| r | -0.36 | -0.26 | 0.14 | 0.61 | 1.00 | 0.78 | 0.72 | 0.77 | 0.16 |
| 0.071 | 0.343 | 0.258 | |||||||
| HAD-D | |||||||||
| r | -0.17 | -0.51 | 0.25 | 0.53 | 0.78 | 1.00 | 0.65 | 0.64 | 0.08 |
| 0.242 | 0.08 | 0.568 | |||||||
| FIQ | |||||||||
| r | -0.22 | -0.31 | 0.21 | 0.72 | 0.72 | 0.65 | 1.00 | 0.82 | 0.16 |
| 0.128 | 0.142 | 0.253 | |||||||
| SSS | |||||||||
| r | -0.18 | -0.24 | 0.31 | 0.48 | 0.77 | 0.64 | 0.81 | 1.00 | 0.26 |
| 0.206 | 0.088 | 0.073 | |||||||
| STDT | |||||||||
| r | 0.29 | 0.44 | 0.15 | -0.03 | r-0.16 | 0.08 | 0.16 | 0.26 | 1.00 |
| 0.767 | 0.31 | 0.799 | 0.258 | 0.568 | 0.253 | 0.073 | |||
| VAS: Visual Analog Scale; HAD-A/HAD-D: Hospital Anxiety and Depression Scale; FIQ: Fibromyalgia Impact Questionnaire; SSS: Symptom Severity Scale; STDT: Somatosensory temporal discrimination threshold. | |||||||||